Relay Therapeutics (RLAY) Shares Outstanding (2019 - 2026)

Relay Therapeutics (RLAY) has reported Shares Outstanding (Entity) for 8 consecutive years, with $189.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 10.98% year-over-year to $189.2 million; the TTM figure through Mar 2026 stood at $189.2 million (up 10.98% YoY), while the FY2025 annual figure was $173.9 million, up 3.64% from the prior year.
• Shares Outstanding (Entity) climbed to $189.2 million in Q1 2026 per RLAY's latest filing, from $173.9 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $189.2 million in Q1 2026 and bottomed at $108.4 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $143.0 million across 5 years, with a median of $132.3 million in 2024.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Entity) gained 1.95% — and 2024, when it surged 35.5%.
• Relay Therapeutics' Shares Outstanding (Entity) stood at $121.1 million in 2022, then advanced by 5.24% to $127.5 million in 2023, then surged by 31.61% to $167.8 million in 2024, then increased by 3.64% to $173.9 million in 2025, then advanced by 8.82% to $189.2 million in 2026.
• Business Quant data shows RLAY's Shares Outstanding (Entity) at $189.2 million in Q1 2026, $173.9 million in Q4 2025, and $172.6 million in Q3 2025.